Correlation Engine 2.0
Clear Search sequence regions


  • blood brain barrier (1)
  • brain (3)
  • human (3)
  • impairs (1)
  • lipid (1)
  • mice (3)
  • midbrain (1)
  • neurons (1)
  • parkinson disease (5)
  • phase (1)
  • phenotypes (2)
  • SCD1 (1)
  • SKO (2)
  • stearoyl- coa (7)
  • tetramer (1)
  • α- synuclein (13)
  • Sizes of these terms reflect their relevance to your search.

    Increasing evidence has shown that Parkinson's disease (PD) impairs midbrain dopaminergic, cortical and other neuronal subtypes in large part due to the build-up of lipid- and vesicle-rich α-synuclein (αSyn) cytotoxic inclusions. We previously identified stearoyl-CoA desaturase (SCD) as a potential therapeutic target for synucleinopathies. A brain-penetrant SCD inhibitor, YTX-7739, was developed and has entered Phase 1 clinical trials. Here, we report the efficacy of YTX-7739 in reversing pathological αSyn phenotypes in various in vitro and in vivo PD models. In cell-based assays, YTX-7739 decreased αSyn-mediated neuronal death, reversed the abnormal membrane interaction of amplified E46K ("3K") αSyn, and prevented pathological phenotypes in A53T and αSyn triplication patient-derived neurospheres, including dysregulated fatty acid profiles and pS129 αSyn accumulation. In 3K PD-like mice, YTX-7739 crossed the blood-brain barrier, decreased unsaturated fatty acids, and prevented progressive motor deficits. Both YTX-7739 treatment and decreasing SCD activity through deletion of one copy of the SCD1 gene (SKO) restored the physiological αSyn tetramer-to-monomer ratio, dopaminergic integrity, and neuronal survival in 3K αSyn mice. YTX-7739 efficiently reduced pS129 + and PK-resistant αSyn in both human wild-type αSyn and 3K mutant mice similar to the level of 3K-SKO. Together, these data provide further validation of SCD as a PD therapeutic target and YTX-7739 as a clinical candidate for treating human α-synucleinopathies. © 2022. The Author(s).

    Citation

    Silke Nuber, Chee Yeun Chung, Daniel F Tardiff, Pascal A Bechade, Thomas D McCaffery, Kazuma Shimanaka, Jeonghoon Choi, Belle Chang, Waseem Raja, Esther Neves, Christopher Burke, Xin Jiang, Ping Xu, Vikram Khurana, Ulf Dettmer, Saranna Fanning, Kenneth J Rhodes, Dennis J Selkoe, Robert H Scannevin. A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2022 Apr;19(3):1018-1036

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 35445353

    View Full Text